Hematology patient reported symptom screen to assess quality of life for AL amyloidosis
Hematology patient reported symptom screen to assess quality of life for AL amyloidosis
复制标题
DOI：
10.1002/ajh.24676
复制
发表时间：
2017-05-01
影响因子：
12.8
通讯作者：
Dispenzieri, Angela
中科院分区：
文献类型：
--
作者：
Warsame, Rahma;Kumar, Shaji K.;Dispenzieri, Angela
轻链淀粉样变性 (AL) 患者通常会延迟诊断并出现明显的症状；这可能会导致生活质量 (QOL) 下降。我们前瞻性地采用血液学患者报告症状筛查 (HPRSS)，这是关于疲劳、疼痛和生活质量的三个问题，得分为 0-10。本研究的目的是更好地了解 QOL 并确定 HPRSS 参数是否可以预测临床结果。 2009年至2014年，纳入了302名新诊断的AL患者。疲劳、疼痛和生活质量的基线中位评分[四分位距]分别为 6 [3,7]、2 [0,5]、5 [3,8]。中位总生存期为 53 个月，第一年有 102 人 (34%) 死亡。寿命超过一年的患者和早逝患者的基线 HPRSS 在疲劳方面存在显着差异（5 [IQR 3, 7] 与 7 [IQR 5, 8]，P
Patients with light chain amyloidosis (AL) often have delayed diagnosis and present with significant symptomatology; this may result in decreased quality of life (QOL). We prospectively employ a Hematology Patient Reported Symptom Screen (HPRSS), which is three questions about fatigue, pain, and QOL, scored 0-10. The aim of this study is to better understand QOL and determine if HPRSS parameters predict for clinical outcomes. From 2009 to 2014, 302 newly diagnosed AL patients were included. Baseline median scores [interquartile range] for fatigue, pain, and QOL were 6 [3,7], 2 [0,5], 5 [3,8], respectively. Median overall survival was 53 months, with 102 (34%) deaths in the first year. There were significant differences in baseline HPRSS between those that lived longer than one year and early death patients in the domains of fatigue (5 [IQR 3, 7] vs. 7 [IQR 5, 8], P